Meningococcal Vaccine Menveo Response in Adolescents

Roger Paul Baxter, MD Co-Director Kaiser Permanente Vaccine Study Center Oakland, CA Interview with:
Roger Paul Baxter, MD
Co-Director Kaiser Permanente Vaccine Study Center
Oakland, CA 94612. What are the main findings of the study?

Dr. Baxter:  Menveo, the currently licensed CRM-conjugate meningococcal vaccine, showed an excellent booster response in adolescents, regardless of which conjugate vaccine they had received previously.  Also, although titers from the priming dose waned, at 3 years there were still protective antibodies in the majority of immunized individuals.  The other US-licensed meningococcal conjugate vaccine, Menactra, uses a different protein conjugate. Were any of the findings unexpected?

Dr. Baxter: No, based on prior studies, and from what is known about conjugate vaccine, a good booster dose was expected.  These are very good vaccines. What should clinicians and patients take away from your report?

Dr. Baxter: This conjugate vaccine provides protection from meningococcal disease with one dose for several years, and a booster drives antibodies to high levels.  The immune response to Group A, the predominant serotype in the African meningococcal belt, is not as good as to the other serotypes, which are more common in the US. What recommendations do you have for future research as a result of this study?

Dr. Baxter: We need to know how long the booster protects, and if there is any way to increase the response to serotype A.



Antibody Persistence and Booster Response of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents.

Baxter R, Reisinger K, Block SL, Izu A, Odrljin T, Dull P
The Journal of Pediatrics – 24 March 2014 (10.1016/j.jpeds.2014.02.025)